Ocumension Therapeutics' OT-802 phase III trial approved in China

Ocumension Therapeutics (HKEX: 1477) announced that it has received clinical trial authorization in China to begin a Phase III clinical trial for OT-802 (pilocarpine hydrochloride), a self-developed product targeting presbyopia. The trial is designed as a randomized, double-masked, placebo-controlled, parallel-group, multi-center study. China's National Medical Products Administration's Center for Drug Evaluation has approved the study. Ocumension highlights the significant commercial potential in the PRC presbyopia treatment market, where currently no pharmaceutical treatment is approved for commercial use. The company emphasizes that OT-802, independently developed by Ocumension, exhibits rapid onset and a favorable safety profile based on preclinical studies. Ocumension possesses exclusive patent rights for the technology used in OT-802.